Search

TGAAC09

It was under investigation in clinical trials NCT00482027 and NCT00888446 for the treatment of HIV Infection. … tgAAC09 is an investigational vaccine that utilizes an AAV vector to deliver genes that encode HIV proteins.

Gallium maltolate

Gallium maltolate is Titan’s novel oral agent in development for the potential treatment of chronic bacterial infections, bone disease and cancer.

XL228

XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation

GlycoPEG-GCSF

GlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.

Cefacetrile

A derivative of 7-aminocephalosporanic acid.

Galiximab

Galiximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.

Lexibulin

CYT997 is an orally available vascular targeting and cytotoxic agent that has proven effective in animal models of a wide range of tumour types including breast, prostate and colon, as well as some leukemias

NP-50301

It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. … The majority of sufferers of DES are postmenopausal women; and clinical research around the world has suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this

Fosfructose

Glyphosate